SCM
BBNX

Soleus Capital Management’s Beta Bionics BBNX Stock Holding History

Soleus Capital Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.6M Buy
4,354,501
+1,819,936
+72% +$26.9M 1.77% 15
2025
Q4 		$77.2M Sell
2,534,565
-1,335,593
-35% -$35.7M 2.85% 10
2025
Q3 		$76.9M Buy
3,870,158
+50,000
+1% +$879K 3.87% 6
2025
Q2 		$55.6M Buy
3,820,158
+424,817
+13% +$6.01M 3.68% 6
2025
Q1 		$41.6M Buy
+3,395,341
New +$63.3M 2.99% 11

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Soleus Capital Management's BBNX Position: Q1 2026 in Review

Soleus Capital Management increased its Beta Bionics (BBNX) stake by 72% in Q1 2026, buying an estimated $26.9M and bringing the position to 4,354,501 shares worth $43.6M. The position accounts for 1.77% of the portfolio, ranked #15.

Soleus Capital Management first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $77.2M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Soleus Capital Management held 4,354,501 shares of Beta Bionics worth $43.6M as of Q1 2026.
  • Soleus Capital Management bought 1,819,936 Beta Bionics shares in Q1 2026, an estimated $26.9M.
  • Beta Bionics made up 1.77% of Soleus Capital Management's portfolio in Q1 2026, its #15 holding.
  • Soleus Capital Management first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • Soleus Capital Management's Beta Bionics position peaked at $77.2M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.